Journal of Medicinal Chemistry

Rational Design of Potent and Selective Inhibitors of an Epoxide Hydrolase Virulence Factor from *Pseudomonas aeruginosa*

Seiya Kitamura,[†] Kelli L. Hvorecny,[‡] Jun Niu,[†] Bruce D. Hammock,[†] Dean R. Madden,[‡] and Christophe Morisseau^{*,†}

[†]Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, One Shields Avenue, Davis, California 95616, United States

[‡]Department of Biochemistry, Geisel School of Medicine at Dartmouth, 7200 Vail Building, Hanover, New Hampshire 03755, United States

Supporting Information



ABSTRACT: The virulence factor cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif) is secreted by *Pseudomonas aeruginosa* and is the founding member of a distinct class of epoxide hydrolases (EHs) that triggers the catalysis-dependent degradation of the CFTR. We describe here the development of a series of potent and selective Cif inhibitors by structure-based drug design. Initial screening revealed **1a** (KB2115), a thyroid hormone analog, as a lead compound with low micromolar potency. Structural requirements for potency were systematically probed, and interactions between Cif and **1a** were characterized by X-ray crystallography. On the basis of these data, new compounds were designed to yield additional hydrogen bonding with residues of the Cif active site. From this effort, three compounds were identified that are 10-fold more potent toward Cif than our first-generation inhibitors and have no detectable thyroid hormone-like activity. These inhibitors will be useful tools to study the pathological role of Cif and have the potential for clinical application.

INTRODUCTION

Pseudomonas aeruginosa is a ubiquitous opportunistic pathogen that infects various sites of the human body, including the lungs in patients with diseases such as chronic obstructive pulmonary disease and cystic fibrosis.¹ The bacterium is naturally resistant to a large range of antibiotics and can acquire additional resistance,² creating a pressing need for novel therapeutic approaches.

Among its strategies for subverting host defenses, *P. aeruginosa* targets the cystic fibrosis transmembrane conductance regulator (CFTR), an ion channel important for epithelial fluid transport, mucociliary clearance and mucosal immunity in the lung.³ *P. aeruginosa* secretes the CFTR inhibitory factor (Cif) that blocks the postendocytic deubiquitination of CFTR and thus facilitates its lysosomal degradation.⁴ Cif is a member of the α/β hydrolase family and has demonstrated epoxide hydrolase (EH) activity.⁵ Using site directed mutations and inhibitors, we observed that Cif EH activity is critical for the inhibition of CFTR deubiquitination. However, the endogenous substrate and exact mechanism of Cif virulence remain unknown, and the mechanistic link between EH activity of Cif and deubiquitination of CFTR still remains speculative. The availability of potent and selective Cif

inhibitors should thus help to better understand Cif pathobiology and to explore possible clinical applications.

We recently identified tiratricol as a moderate Cif inhibitor with an IC₅₀ of 4.7 μ M.^{5b} This compound protects CFTR from both purified Cif protein and P. aeruginosa PA14 applied to polarized human airway epithelial cells.^{5b} This suggests that inhibition of the EH activity of Cif could be a therapeutic approach to maintain CFTR levels on the surface of epithelial cells following Pseudomonas infection, thus permitting faster elimination of the pathogenic bacteria. However, tiratricol binds the endogenous human liver nuclear thyroid hormone receptor with subnanomolar affinity. In fact, tiratricol has a higher affinity than the endogenous thyroid hormone T₃ (triiodothyronine),⁶ consistent with reports of severe side effects that led the FDA to suspend the availability of tiratricol.⁷ Relatively low potency toward Cif and extremely high potency toward the thyroid hormone receptor thus limit the application of tiratricol for further biological studies and possible human clinical application.

Received: February 1, 2016



Figure 1. Structures of lead compounds and their potency are shown, while a general structure for Cif inhibitors and the substrate used for Cif assay are below.

Scheme 1. General Synthetic Scheme^a



"Reagents and conditions: (a) NaOH_{aq}, DMF; (b) BBr₃, DCM; (c) Na₂S₂O₄, THF/H₂O, 50 °C; (d) R-COCl, MTBE, saturated NaHCO_{3 aq} or 1 M NaOH_{aq}.

To circumvent the limitations of tiratricol, in this report, we identified related compounds and studied the interactions required for Cif inhibition, using two complementary approaches: chemical modification and X-ray crystallography of inhibitor complexes. On the basis of the results from both approaches, we designed and synthesized compounds with improved potency toward Cif and with no detectable thyroid hormone-like activity in a transgenic reporter system.

RESULTS AND DISCUSSION

Initial Screening Based on the Tiratricol Structure. Initial screening of commercially available and synthetic⁸ compounds similar to the tiratricol structure (Table S1 in Supporting Information) revealed 1a (KB2115⁹) to be slightly more potent than tiratricol. While 1a is also a ligand selective for the thyroid hormone receptor β ,^{9,10} 1a does not contain any iodine atoms, in contrast to tiratricol (Figure 1). Given the potency and relative ease of analog synthesis, 1a represents a better initial lead compound for medicinal chemistry approaches to improve its potency against Cif.

Probing the Structural Requirements of Lead Compound 1a for Cif Inhibition. On the basis of the general structure of the Cif inhibitors shown in Figure 1, we explored the structural requirements of Cif inhibition by 1a more rigorously. Compound 1a analogs were synthesized using methods similar to the one previously described for thyroid hormone analogs as shown in Scheme 1.¹¹ Briefly, S_NAr reaction between a phenol 2 and compound 3 gave a diphenyl ether 4. Deprotection of a methoxy moiety by boron tribromide yielded a phenol 5. The nitro group was then reduced into a primary amine 6 using sodium dithionite. Finally, an amide bond was formed by reacting the aniline 6 with acid chloride.

The requirement for the R₁ functional group was studied first (Table 1). Compounds with a primary amine (6a) or a nitro moiety (5a) still possessed inhibitory activity, although potency dropped approximately 3-fold. Inhibitory activity was also modestly affected when the primary amine was replaced by an alkylamide (1b, 1c). The ethyl ester form of the lead compound (1d) was also slightly less potent than the free acid form (1a). The compound with an additional methylene moiety (1e) was as potent as 1a, with the ethyl ester form (1f) having slightly lower inhibitory activity than the free acid form. These data suggest that the terminal free carboxylic moiety interacts only weakly with the enzyme. In further synthesis of analogs for this initial study, we encountered difficulty in purifying some of the analogs with free acid forms on R₁. Therefore, the malonate ethyl ester moiety was selected as R₁ for the purpose of determining structural requirements at other positions.

Results for the structural requirements of the R₂, R₃, R₄, and R₅ functional groups are shown in Table 2. When the hydroxyl moiety at R₂ was replaced by either hydrogen (**1g**) or methoxide (**1h**), these analogs failed to show inhibitory activity at 50 μ M or 25 μ M, suggesting that the hydroxyl moiety is critical for inhibitory activity and that a hydrogen bond acceptor is not sufficient for the interaction. Replacement of bromines on R₃ and R₃' with chlorines (**1i**) resulted in an approximately 2-fold increase in activity. Removal of one of the

Table 1. Effect of R₁ Moiety on Cif Inhibitory Potency



 $^{\prime\prime}IC_{50}$ values were determined with a fluorescent-based assay using CMNGC as a fluorescent reporter substrate (see methods section). Reported IC₅₀ values are the average of triplicates with at least two data points above and at least two below the IC₅₀. The fluorescent-based assay as performed here has a standard error between 10% and 20%, suggesting that differences of 2-fold or greater are significant.

Table 2. Effect of R₂-R₅ Moieties on Cif Inhibitory Potency



compd	R_2	R ₃	R_4	R_5	$IC_{50}^{a}(\mu M)$
1d	OH	R3 = R3' = Br	isopropyl	Н	6.7
1g	Н	R3=R3'=Br	isopropyl	Н	>50
1h	OCH3	R3 = R3' = Br	isopropyl	Н	>25 ^b
1i	OH	R3 = R3' = Cl	isopropyl	Н	3.8
1j	OH	R3=Cl, R3'=H	isopropyl	Н	11.6
1k	OH	R3 = R3' = Cl	Н	Н	>50
11	OH	R3 = R3' = Cl	Br	Н	4.9
1m	OH	R3 = R3' = Cl	I	Н	3.8
1n	OH	R3 = R3' = Cl	CF3	Н	3
1p	OH	R3 = R3' = Cl	ethynyl	Н	2.9
1q	OH	R3 = R3' = Cl	Н	Br	29.3

^{*a*}IC₅₀ values were determined with a fluorescent-based assay using CMNGC as a fluorescent reporter substrate (see methods section). Reported IC₅₀ values are the average of triplicates with at least two data points above and at least two below the IC₅₀. The fluorescent-based assay as performed here has a standard error between 10% and 20%, suggesting that differences of 2-fold or greater are significant. ^{*b*}Limited by the solubility (25 < *S* < 50 μ M) of the compound under assay conditions (1% DMSO, 0.1 mg/mL BSA at 37 °C). Solubility was measured using a previously described method.²⁹

chlorines (1j) led to a decrease in activity, reflecting the importance of the halide R_3 substituents.

Replacement of the R_4 isopropyl with a proton yielded the nonsubstituted compound (1k), which showed no inhibition at 50 μ M, indicating that the substituent at R_4 is critical for potency. Replacement of the isopropyl moiety with bromine (11), iodine (1m), trifluoromethyl (1n), or acetylene (1p) moieties did not change the potency of the compound. This suggests the existence of available space in the binding pocket of Cif that can be filled by an R_4 substituent of the appropriate steric volume but that its exact chemistry is not precisely constrained. A compound with bromine at the R_5 position (1q) had potency much lower than the unsubstituted compound (1k), reflecting greater selectivity at the R_5 position.

Replacing the R_4 isopropyl moiety with a trifluoromethyl moiety (1n), which is a strong electron withdrawing group, increases the acidity of the phenol on R_2 . Thus, we expected that compound 1n would form stronger hydrogen bonds, leading to higher inhibitory potency. However, compared to 1i, the potency of 1n did not improve dramatically.

Cif:1a Structure. In parallel with our SAR studies, we determined the X-ray crystallographic structure of Cif complexed with lead compound **1a** at a resolution of 1.65 Å (Figure 2A, Table S2, Figures S1 and S2). The resulting model revealed that **1a** occludes access of the substrates to the catalytic pocket (Figure 2B). In general, the structure



Figure 2. X-ray crystal structure of lead compound 1a in complex with Cif. (A) A C_a -trace shows the conformation of the Cif dimer, with active-site side chains and 1a included as stick figures. (B) An expansion of the chain B inset highlighted in (A) displays the hydrogen bonding network and ring-stacking interaction (dashed lines) formed among 1a, an acetate ion (green carbons), water molecules (green spheres), and active-site residues (carbons from catalytic residues in green; others in gray). Compound 1a blocks entrance to the active site from the upper right. Potential bonds with halogens are shown in Figure S3. (C) The Cif active site rotated by roughly 135° highlights the hydrogen bonding network that connects Cif, 1a, and a bound acetate ion. (D) The same view of apo Cif (cyan carbons and waters) shows the conserved positions of active-site side chains. Non-carbon atoms are colored by element (O, red; N, dark blue; Br, maroon).

confirmed the findings from our medicinal chemistry approach. For example, the structure showed that the R_1 moiety is located outside the active-site tunnel and is not critical for the interaction with Cif (Figure 2B), consistent with our SAR data showing that changes in the R₁ chain have little effect on Cif inhibitory potency (Table 1). The structure also showed that the hydroxyl moiety at the R₂ position forms a hydrogen bond with the main-chain carbonyl oxygen of Gly270 (Figure 2). This supports our observation that removing this hydroxyl moiety resulted in great loss of potency (Table 2). One of the bromines (R_3) is close to the hydroxyl of Ser173 and the mainchain amide nitrogens of Leu174 and Val175, while the other bromine (R_3') is close to the thioether of Met272, indicating potential interactions between the halogens and these residues (Figure S3).¹² In addition, the dibromophenyl ring of compound 1a appears to form a π -stacking interaction with Phe164, which may be strengthened by halogen substituents (Figure 2B).¹³ The catalytic cavity opens around the isopropyl moiety of 1a, indicating that larger groups could be present at position R4, as we observed with our medicinal chemistry approach (Table 2).

The structural requirements of Cif inhibitors overlap with those of thyroid hormone receptor ligands^{10a} at several positions. Tiratricol and 1a reflect the intersection of these requirements and thus serve as both thyroid hormone mimics and Cif inhibitors.^{5b} For example, the hydroxyl group on R₂ and two halogens on R_3 and R_3' are required in both cases, and a bulky substituent is preferred on R₄. In the case of the thyroid hormone receptor, the terminal free acid of R₁ forms hydrogen bonds (Figure S4). On the other hand, the terminal free acid is not required for Cif inhibition (Table 1). Therefore, compounds with different R1 groups were screened to evaluate their thyroid hormone activity.¹⁴ The compound with propyl amide (1c) showed the lowest thyroid hormone activity while still effectively inhibiting Cif (Table S3, Figure S5). Therefore, the propylamide moiety was selected as the R1 moiety for further structural optimization.

Comparison to Mammalian EHs and Their Inhibitors, and Inhibitor Design Strategy. In the case of mammalian epoxide hydrolases, urea and amide moieties are known to function as transition state analogs.¹⁵ These moieties bind to the catalytic site very tightly by interacting noncovalently with the catalytic nucleophile Asp and the accessory Tyr-Tyr pair, leading to potent inhibition of these enzymes.^{15a,c,16} Cif has a conserved EH catalytic triad consisting of residues Asp129, Glu153, and His297, while it uses a noncanonical His177-Tyr239 accessory pair to coordinate the epoxide oxygen during ring opening.^{5c} On the basis of the similar active-site chemistry, we expected that urea or amide functionalities could also interact with the catalytic site of Cif. However, simple alkyl urea/amide/carbamate compounds failed to show Cif inhibitory activity at 50 μ M, as did a series of additional potent mammalian EH inhibitors with urea or amide pharmacophores (Table S4). The differential sensitivity of the mammalian and bacterial EHs is consistent with our previous discovery that they differ in the relative kinetics of formation vs hydrolysis of a covalent intermediate¹⁷ and suggests that the fine details of the transition states of the two EH families are distinct.

In the Cif:1a complex structure, an acetate ion was found in the catalytic site of the enzyme (Figure 2B and Figure 2C), which was crystallized in a buffer containing sodium acetate. The active-site hydrogen bonding network includes interactions between the acetate ion and the catalytic site residues Asp129, His177, and Tyr239 (Figure 2C), replicating many of the interactions of the local water network observed in the apo structure (Figure 2D). The distance between the isopropyl moiety and the acetate is roughly 4.5 Å (Figure 2B). The theoretical distance between the carbonyl and phenyl ring in compounds that have a phenyl carbonyl moiety at the R_4 position is approximately 4.3 Å, indicating that a phenyl linker may have the appropriate length to reach the catalytic site.

Improving Potency by Targeting the Catalytic Site. On the basis of the above results, we hypothesized that the inhibitory potency toward Cif could be improved by connecting the lead compound to a moiety that directly interacts with catalytic residues. A series of compounds were designed to target the catalytic site by extending the R_4 position. As shown in Scheme 2, these compounds were synthesized by Suzuki–

Scheme 2. Synthesis of Compounds 8a-k by Suzuki-Miyaura Coupling^a



"Reagents and conditions: R_6 -phenylboronic acid or ester, $Pd(PPh_3)_4$, Na_2CO_3 , DME/EtOH/H₂O, 71 °C.

Miyaura cross coupling between an iododiphenyl ether 7 and various substituted phenylboronic acids or esters, using $Pd(PPh_3)_4$ as a palladium catalyst and sodium carbonate as a base.¹⁸ Their potencies as Cif inhibitors are shown in Table 3.

A compound with para carboxylic acid (8b) showed a significant loss of activity, while compounds with para amide (8c), urea (8h), or ketone (8j) showed potencies almost 10fold higher than that of the lead compound, reaching the theoretical limit of quantification (half of the enzyme concentration) of our fluorescent-based Cif inhibition assay ([E] = 0.6 μ M in the assay). For more classical epoxide hydrolases, ureas and amides are pharmacophores for potent inhibitors that establish bonds with catalytic residues, but ketones are not,^{16b} underscoring the distinct chemistry of the Cif active site. In the case of free amides, both para (8c) and meta (8d) substituents yielded high potencies, with the para substituent slightly favored. In the case of nitrile, the meta substituent $(\mathbf{\tilde{8f}})$ showed higher potency but the para substituent (8e) showed significant decrease in potency. Compounds with a methylamide (8g) or a sulfonamide substituent (8k) also showed significantly lower potency than corresponding free amide.

Surface Plasmon Resonance (SPR). To confirm potency, particularly for our highest-affinity compounds, binding interactions between Cif and inhibitors were further examined by surface plasmon resonance (SPR). Results are shown in Table S5 and Figure S6. Compound 1a and tiratricol showed similar affinity (K_D), and compounds 8c, 8h, and 8j showed 30-to 50-fold higher affinity than lead compound 1a. Overall, the affinity values from the SPR experiments were approximately 10- to 40-fold weaker than the IC₅₀ values obtained from the enzyme activity-based assay. Discrepancies between SPR and solution phase experiments have been reported in several protein–ligand interaction analyses¹⁹ and may be due to conformational change by immobilization on the chip surface, cooperative effects, or differences in experimental conditions,

 Table 3. Inhibitory Potency of a Series of Compounds

 Designed To Target the Catalytic Site of Cif



 ${}^{a}IC_{50}$ values were determined with a fluorescent-based assay using CMNGC as a fluorescent reporter substrate (see methods section). Reported IC₅₀ values are the average of triplicates with at least two data points above and at least two below the IC₅₀. The fluorescent-based assay as performed here has a standard error between 10% and 20%, suggesting that differences of 2-fold or greater are significant.

such as the presence of surfactant and DMSO concentration in the running buffer. Identification of the cause of this discrepancy is the subject of further research. The dissociation rate constants (k_d ; Table S5) suggest that 8c, 8h, and 8j have residence times between 2 and 4 s. This is much shorter than the best inhibitors for the human soluble epoxide hydrolase (sEH),²⁰ suggesting that further optimization of Cif inhibitors is possible.

Structures of Second-Generation Cif Inhibitors. To further characterize the interaction between the new inhibitors and the Cif protein, we pursued a cocrystallization strategy and determined structures of the resulting complexes by X-ray diffraction. As shown in Figure 3A and Figure 3B, the amide or urea moieties in compounds 8c (purple) and 8h (blue) interact with catalytic residues: the nucleophile Asp129, and Tyr239 and His177, which coordinate with the epoxide substrate.^{5a} The NH group of amide and urea forms hydrogen bonds with Asp129, while the oxygen in the carbonyl forms hydrogen bonds to His177 and Tyr239. As with the acetate in the Cif:1a structure, the binding of 8c and 8h occupies the volume and thus replaces the tetrahedral water network found in the apo crystal structure (Figure 2D, cyan). By shifting the specific hydrogen-bonding network in the active site, 8c and 8h promote a hydrogen bond between His297 and Asp129. This new bond displaces the hydrogen bond with the catalytic water that is activated by the His297/Glu153 pair under hydrolysis conditions.

The structures also provide a framework to interpret the structure-activity relationship of Cif inhibitors targeting the



Figure 3. X-ray structures of Cif:8c (A, purple carbons) and 8h (B, blue carbons) complexes, with respective hydrogen bonding networks represented by dashed lines for chain B. Carbon atoms of catalytic and noncatalytic residues are shown in the same color as the corresponding ligand and in gray, respectively. Potential bonds with halogens are not shown. Non-carbon atoms are colored by element (O, red; N, dark blue; Cl, green).

catalytic site (Table 3, Table S5). It appears that the meta substituents (8d and 8f) can each be accommodated at the edge of the catalytic core. Interestingly, among the para substituents either an amide (8c), a urea (8h), or a ketone (8j) moiety causes a substantial increase in potency against Cif. Although chemically distinct, each of these groups can be sterically accommodated between the catalytic aspartic acid and the ring-opening pair, forming hydrogen bonds that lie roughly within the plane of view defined by Figure 3. In contrast, weaker binding affinities are observed for para substituents with charge incompatibility (8b), out-of-plane hydrogen-bond orientations (8k), or a combination of steric and hydrogen-bonding incompatibility (8e, 8g, 8i).

Selectivity Profile and in Vitro Metabolic Stability of Selected Compounds. Three inhibitors, 8c, 8h, and 8j, were selected based on their Cif inhibitory potency (Table 3). Thyroid receptor induction activity (relative to 10 nM T₃) was measured at a concentration of 10 μ M. Results (Table 4) showed that compounds 8c, 8h, and 8j lost their thyroid hormone agonistic activity (EC₅₀ > 10 μ M), while they displayed a weak antagonistic activity (Table 4, Tables S6 and S7). Globally, compared to 1a, the novel Cif inhibitors are more than 150 000-fold more selective for Cif than for the thyroid hormone receptor. Next, inhibition of human sEH and microsomal epoxide hydrolase (mEH) was measured. The IC_{50} values obtained (~8 μ M for sEH and 20–100 μ M for mEH) are 100- to 10 000-fold higher than the best inhibitors for these enzymes,^{16b} suggesting that 8c, 8h, and 8j are poor inhibitors for the mammalian EHs. Given the potency of these compounds against Cif, they have at least a 27-fold selectivity toward Cif over sEH and at least a 50-fold selectivity toward Cif over mEH.

Metabolic stability of the three selected compounds was then studied in both liver microsomes and cell cultures.²¹ Results (Table 4) indicate that compound **8h** is the most stable of the trio, followed in order by **8c** and **8j**. Compound **8a**, which does not have a substituent on the biphenyl ring (Table 3), had a half-life longer than 60 min in the human liver microsomal stability assay (63% remained after 60 min incubation). This value is more than double the corresponding value for **8h**, suggesting that the substituent on the biphenyl ring is the most susceptible to metabolism. It should be noted that phenolic moieties are subject to phase II metabolic processes such as glucuronidation and sulfation,²² which could increase the

	Гable 4. Selectivi	ity Profiles, in	Vitro Metabolic Stabilit	y, and Physicochemical	Properties of Selected	Compounds
--	--------------------	------------------	--------------------------	------------------------	-------------------------------	-----------

	compound				
parameter	1a	8c	8h	8j	
TR agonist EC ₅₀ (nM)	0.43 ± 0.14	>10 000	>10 000	>10 000	
TR antagonist (% inhibition at 10 μM)		66	28	33	
human sEH IC ₅₀ $(\mu M)^a$		8.6	7.5	7.7	
human mEH IC ₅₀ $(\mu M)^{b}$		17.2	26.3	97.8	
human liver microsomal stability $t_{1/2}$ (min)		15	29	5.7	
stability in cell culture (%) ^c		106 ± 8	103 ± 12	74 ± 30	
molecular weight	487	445	460	444	
melting point (°C)		261.3-262.0	162.0-162.9	190-194	
$\log P^d$	4.71	4.44	4.11	4.85	
solubility $(\mu M)^e$		0.17	21	<0.04	
mouse plasma protein binding $^{f}(\%)$	99	>99	>99	>99	

^{*a*}Measured using *t*-DPPO ([³H]-*trans*-diphenylpropene oxide) as a substrate. The IC₅₀ of 12-(3-adamantan-1-ylureido)dodecanoic acid is 16 nM. ^{*b*}Measured using CMNGC as a substrate. The IC₅₀ of 2-(nonylthio)propanamide is 6.0 μ M. ^{*c*}Percentage remaining after a 24 h incubation (initial conc: 10 μ M) with GH3.TRE-Luc cell (mean \pm SD). ^{*d*}Predicted value using Chembiodraw Ultra 13.0. ^{*c*}Equilibrium solubility measured in sodium phosphate buffer (0.1 M, pH 7.4) without cosolvent or BSA at room temperature. ^{*f*}Measured at 1 μ M using a rapid equilibrium dialysis device (no. 89809, Thermo Scientific, IL) as described previously.³⁵

clearance and thus decrease the bioavailability of these compounds in vivo.

Finally, we investigated the physicochemical properties of the selected compounds. While the three compounds have similar molecular weight, compound 8h has a lower melting point. In addition, this compound has a lower predicted $\log P$ and much higher aqueous solubility, without DMSO as a cosolvent, than 8c and 8j, suggesting that 8h should be easier to formulate and should be more bioavailable. As expected from their lipophilicity, these compounds showed high plasma protein binding, which may limit their target accessibility and thus hamper their efficacy in vivo. It should be noted, however, that plasma protein binding could also help drug solubilization and distribution in the body.²³ Note that the reported Cif IC₅₀ values were determined in the presence of high BSA concentration (0.1 mg/mL) to make the assay more representative of in vivo conditions. In terms of toxicity in vitro, neither 8c nor 8h showed cytotoxicity when applied to GH3.TRE-Luc cells or polarized monolayers of airway epithelial cells at concentrations up to 10 μ M (Figures S7 and S8). Overall, in terms of potency, selectivity, metabolic stability, solubility, and toxicity, compound 8h is the most suitable for further in vitro and in vivo experiments to determine efficacy of Cif inhibitors against Pseudomonas infection.

CONCLUSION

Here we describe a series of potent and selective Cif inhibitors, rationally designed by combining insights from classical medicinal chemistry and crystallographic analysis of Cif-lead binding interactions. Compounds synthesized using this strategy show an approximately 10-fold increase in inhibitory potency toward the primary target and also a more than 15 000-fold decrease in the critical off-target potency toward thyroid hormone receptor. The binding of these second-generation inhibitors was further analyzed by SPR and X-ray crystallog-raphy.

Given their in vitro stability and physicochemical properties (Table 4), these inhibitors may have a short half-life, low bioavailability, and low accessibility to the target enzyme in vivo. Nevertheless, because of their increased potency against Cif and lack of thyroid hormone-like activity (Table 4), these

new inhibitors will be useful in the study of the mechanisms of Cif virulence, as well as determining the in vivo functions of Cif and the efficacy of Cif inhibitors against *Pseudomonas* infection. Cif prevents deubiquitination of CFTR by ubiquitin specific peptidase 10.²⁴ To our knowledge, there are no reports of endogenous epoxides or diols that regulate the ubiquitin/ proteasome system. An approach combining inhibitors and metabolomics should help identify the endogenous substrates of Cif.²⁵ These inhibitors not only are improved Cif inhibitors but also represent potential inhibitors of bacterial EHs with similar active-site geometries.

EXPERIMENTAL SECTION

General. All reagents and solvents were purchased from commercial suppliers and were used without further purification. Compound 1a was purchased from Cayman Chemicals (purity ≥98%). All reactions were performed in an inert atmosphere of dry nitrogen or argon. Melting points were determined using an OptiMelt melting point apparatus. ¹H and ¹³C NMR spectra were collected using a Varian 600, 400, or 300 MHz spectrometer with chemical shifts reported relative to residual deuterated solvent peaks or a tetramethylsilane internal standard. Accurate masses were measured using an LTQ orbitrap hybrid mass spectrometer (HRMS) or Micromass LCT ESI-TOF-MS (ESI-TOF-MS). The purity of the compounds that were tested in the assay was determined by reverse phase HPLC-DAD and found to be >95% based on monitoring absorption at 254 nm. Reactions were monitored on TLC plates (silica gel matrix, fluorescent indicator, Sigma-Aldrich, 99569), and spots were either monitored under UV light (254 mm) or stained with phosphomolybdic acid. The same TLC system was used to test purity, and all final products showed a single spot on TLC with both phosphomolybdic acid and UV absorbance, and when measured gave a sharp melting point for crystalline compounds. FT-IR spectra were recorded on a Thermo Scientific NICOLET IR100 FT-IR spectrometer. The elemental analysis was conducted by Midwest Microlab, Indianapolis, IN. Compound 1a analogs were synthesized using methods similar to the one previously described for thyroid hormone analogs.¹¹ Chemical characterization of representative compounds is described below, and others are included in detailed synthetic methods in Supporting Information.

General Procedure A: S_NAr . To an ice-cold DMF solution of phenol 2 (1.1 equiv) was slowly added 1 M NaOH_{aq} (1.1 equiv), followed by compound 3 (1.0 equiv) in DMF. The reaction was slowly warmed up to rt and stirred for 1–24 h. To this solution was added water. The mixture was extracted with hexane/ethyl acetate (5:1)

mixture three times. The organic layer was combined, washed with brine, dried over $MgSO_4$, filtered, and concentrated in vacuo.

1,3-Dibromo-2-($\bar{3}$ -isopropyl-4-methoxyphenoxy)-5-nitrobenzene (4a). Compound 4a was synthesized from 3-isopropyl-4-methoxyphenol (2a) and 1,3-dibromo-2-iodo-5-nitrobenzene (3a) to give the desired product (1.85 g, 85%) as a yellow powder. ¹H NMR (600 MHz, CDCl₃) δ 8.50 (s, 2H, H-7, H-9), 6.81 (d, *J* = 3.5 Hz, 1H, H-1), 6.71 (d, *J* = 9.2 Hz, 1H, H-4), 6.43 (dd, *J* = 8.9, 3.5 Hz, 1H, H-5), 3.79 (s, 3H, CH₃O), 3.30–3.28 (m, 1H, isopropyl CH), 1.18 (d, *J* = 6.9 Hz, 6H, isopropyl (CH₃)₂). ¹³C NMR (151 MHz, CDCl₃) δ 155.5, 152.9, 150.0, 145.0, 139.3, 128.5, 119.5, 114.4, 111.9, 111.0, 55.9, 27.1, 22.6.

General Procedure B: Deprotection of Methoxy Moiety. To an ice-cold DCM solution of diphenylether 4, a 1 M boron tribromide (1.2 equiv) solution in DCM was added dropwise. The reaction was slowly warmed up to rt and stirred for 1-24 h. To this solution was slowly added methanol at 0 °C, then warmed to rt. The solution was washed with saturated NaHCO₃ aqueous solution, and the aqueous layer was extracted with DCM three times. The organic layer was combined and washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo.

4-(2,6-Dibromo-4-nitrophenoxy)-2-isopropylphenol (**5a**). Compound **5a** was synthesized from **4a** to give the desired product (1.9 g, quant) as a yellow powder; mp 106–107 °C; ¹H NMR (600 MHz, CDCl₃) δ 8.50 (s, 2H, H-7, H-9), 6.79 (d, J = 3.1 Hz, 1H, H-1), 6.65 (d, J = 8.7 Hz, 1H, H-4), 6.39 (dd, J = 8.7, 3.1 Hz, 1H, H-5), 4.54 (s, 1H, OH), 3.18 (septet, J = 6.9 Hz, 1H, isopropyl CH), 1.23 (d, J = 6.9 Hz, 6H, isopropyl (CH₃)₂). ¹³C NMR (151 MHz, CDCl₃) δ 155.5, 150.2, 148.8, 145.0, 136.7, 128.6, 119.4, 116.0, 114.4, 112.6, 27.5, 22.5. ESI-TOF-MS (+) calcd for C₁₅H₁₄Br₂NO₄ (M + H)⁺ 429.92, found 429.89. Purity (HPLC–UV): 95% ($t_{\rm R} = 13.0$ min).

General Procedure C: Reduction of Nitro Moiety to a Primary Amine. To a THF solution of compound 5 (1.0 equiv) was added an aqueous solution of sodium dithionite (3.8 equiv) at rt, then the solution was heated to 50 °C and stirred 1–24 h. After cooling to rt, aqueous 1 M HCl was added, and then the solution was neutralized by a solution of saturated NaHCO₃. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The organic layer was combined and washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo.

4-(4-Amino-2,6-dibromophenoxy)-2-isopropylphenol (**6a**). Compound **6a** was synthesized from **5a** to give the desired product (1.38 g, 87%) as yellowish crystals; mp 186–187 °C; ¹H NMR (600 MHz, DMSO-*d*₆) δ 8.93 (s, 1H, OH), 6.87 (s, 2H, H-7, H-9), 6.64 (d, *J* = 8.7 Hz, 1H, H-4), 6.60 (d, *J* = 3.1 Hz, 1H, H-1), 6.25 (dd, *J* = 8.7, 3.1 Hz, 1H, H-5), 5.53 (s, 2H, NH₂), 3.14 (septet, *J* = 6.9 Hz, 1H, isopropyl CH), 1.10 (d, *J* = 6.9 Hz, 6H, isopropyl (CH₃)₂). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 150.1, 149.1, 148.2, 137.8, 135.3, 118.0, 117.0, 115.2, 112.6, 111.3, 26.5, 22.4. ESI-TOF-MS (+) calcd for C₁₅H₁₆Br₂NO₂ (M + H)⁺ 399.95, found 399.94. Purity (HPLC–UV): 99% (*t*_R = 10.9 min).

General Procedure D: Amide Bond Formation. To an ice-cold MTBE solution of aniline **6** (1.0 equiv) was added a solution of saturated NaHCO₃ or 1 M NaOH, followed by slowly adding the corresponding acid chloride (1.1 equiv). This solution was stirred at rt for 1-24 h, then 1 M HCl aqueous solution was added. The reaction mixture was extracted with ethyl acetate. The organic layer was combined and washed with 1 M HCl_{aq} twice, saturated aqueous NaHCO₃ solution 4 times, and brine, dried over MgSO₄, filtered, and concentrated in vacuo. The target compound was purified by column chromatography and further purified by recrystallization from acetone/DCM/hexane when possible.

N-(3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamide (**1b**). Compound **1b** was synthesized from **6a** and acetyl chloride to give the desired product (99 mg, 56%) as a white powder; mp 172–173 °C; ¹H NMR (600 MHz, DMSO- d_6) δ 10.24 (s, 1H, NH), 9.02 (s, 1H, OH), 7.96 (s, 2H, H-7, H-9), 6.67–6.64 (m, 2H, H-1, H-4), 6.26 (dd, *J* = 9.4, 2.2 Hz, 1H, H-5), 3.16–3.14 (m, 1H, isopropyl CH), 2.07 (s, 3H, COCH₃), 1.11 (d, *J* = 7.0 Hz, 6H, isopropyl (CH₃)₂). ¹³C NMR (151 MHz, DMSO- d_6) δ 168.8, 149.5, 149.3, 143.8, 138.2, 135.6, 122.7, 117.8, 115.3, 112.8, 111.4, 26.5, 24.0, 22.3. ESI-TOF-MS (–) calcd for $C_{17}H_{16}Br_2NO_3$ (M – H)[–] calcd 439.96 found 439.97. Purity (HPLC–UV): 98% ($t_R = 10.8$ min).

General Procedure E: Suzuki–Miyaura Coupling. To a DME solution of compound 7 (80 mg, 177 μ mol, 1.0 equiv) were added Pd(PPh₃)₄ (10 mg, 8.7 μ mol, 0.05 equiv), an aqueous solution of Na₂CO₃ (400 mg in 1 mL of H₂O), and corresponding boronic acid or boronate ester (212 μ mol, 1.2 equiv) in 1 mL of ethanol. This solution was stirred at 71 °C overnight. After cooling to rt, ethyl acetate and 1 M HCl_{aq} were added and extracted 4 times with ethyl acetate. The organic layer was combined and washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo. The target compound was purified by column chromatography and recrystallized from acetone/DCM/ hexane.

5'-(2,6-Dichloro-4-propionamidophenoxy)-2'-hydroxy[1,1'-biphenyl]-4-carboxamide (8c). Compound 8c was synthesized from compound 7 and 4-aminocarbonylphenylboronic acid. The product was obtained as an off-white powder (14 mg, 18%); TLC $R_f = 0.4$ (DCM/MeOH = 30:1); mp 261.3-262.0 °C; IR (neat) 3339 (broad), 1648, 1592, 1532, 1531, 1462 cm⁻¹; ¹H NMR (600 MHz, DMSO- d_6) δ 10.22 (s, 1H, NH), 9.48 (s, 1H, OH), 7.96 (s, 1H, NHH), 7.88–7.83 (m, 2H, biphenyl-H₂), 7.82 (s, 2H, H-7, H-9), 7.57-7.55 (m, 2H, biphenyl-H₂), 7.34 (s, 1H, NHH), 6.90 (d, J = 8.8 Hz, 1H, H-4), 6.75 (d, J = 3.1 Hz, 1H, H-1), 6.64 (dd, J = 8.8, 3.2 Hz, 1H, H-5), 2.34 (q, J = 7.5 Hz, 2H, CH_2), 1.09 (t, I = 7.5 Hz, 3H, CH_3). ¹³C NMR (151 MHz, DMSO-d₆) δ 172.6, 167.7, 149.7, 149.6, 141.5, 140.6, 137.7, 132.6, 128.7, 128.6, 127.6, 127.2, 119.1, 117.1, 116.0, 114.8, 30.7, 9.4. HRMS (+) calcd for C₂₂H₁₉Cl₂N₂O₄⁺ (M + H) 445.0716. Found 445.0717. Purity (HPLC–UV): 99% ($t_{\rm R}$ = 9.2 min). Anal. C 59.09, H 4.14, N 6.13%, calcd for $C_{22}H_{18}Cl_2N_2O_4,$ C 59.34, H 4.07, N 6.29%.

Cif Preparation. Recombinant Cif-His was prepared as described previously. ^{Sb,26} Stocks of purified proteins were stored at 4 °C until used. Since esterase and glutathione transferases can give a high background fluorescence when using cyano(6-methoxynaphthalen-2-yl)methyl glycidyl carbonate (CMNGC) as Cif substrate, it is important to evaluate the purity of Cif for the absence of these and of similar biochemicals. The purified enzyme was tested for contamination with esterase activity and glutathione transferase activity as previously described.²⁷

Fluorescent-Based Cif Inhibitory Assay. IC₅₀ values were determined using a sensitive fluorescent-based assay similar to the method previously described for other EHs.^{5b,28} Cyano(6-methoxy-naphthalen-2-yl)methyl glycidyl carbonate (CMNGC) was used as a fluorescent reporter substrate. Recombinant Cif (0.6 μ M) was incubated with inhibitors for 5 min in sodium phosphate buffer (20 mM, pH 7.0) containing 50 mM NaCl and 0.1 mg/mL of BSA at 37 °C prior to substrate introduction ([S] = 25 μ M).

Activity was measured by determining the appearance of the 6methoxy-2-naphthaldehyde with an excitation wavelength of 330 nm and an emission wavelength of 465 nm for 10 min. Reported IC₅₀ values are the average of triplicates with at least two data points above and at least two below the IC₅₀. The fluorescent-based assay as performed here has a standard error between 10% and 20%, suggesting that differences of 2-fold or greater are significant. Control experiments without Cif (inhibitor and substrate) were used to evaluate the intrinsic fluorescence of inhibitors. For compounds showing IC₅₀ > 50 μ M (compounds 1g, 1h, and 1k), solubility under assay conditions was measured using a method described previously.²⁹ Compounds 1g and 1k showed solubility 50 < *S* < 100 μ M, while compound 1h showed 25 < *S* < 50 μ M.

Surface Plasmon Resonance. The interactions between Cif and inhibitors were analyzed by surface plasmon resonance using a BIAcore T100. The running buffer for immobilization was HBS-P (pH 7.4), which contains 10 mM HEPES, 150 mM NaCl, and 0.05% (v/v) Tween 20 surfactant. Cif was coupled to the surface of a CMS sensor chip using standard amine-coupling chemistry with a 7 min injection of Cif (15 μ g/mL) diluted in 10 mM sodium acetate (pH 4.5). Cif protein was immobilized at 4000–5000 RU. Remaining activated groups were blocked with a 7 min injection of 1 M ethanolamine HCl (pH 8.5). Binding assays were performed at 37 °C at a flow rate of 30 μ L/min with a 40 s injection of inhibitors followed by washing with

Journal of Medicinal Chemistry

buffer for 40 s. Sodium phosphate buffer (20 mM pH 7.0) containing 50 mM NaCl and 0.05% (v/v) Tween 20 with 4% (v/v) DMSO was used as a running buffer in the assay. The measured signals were double-referenced from reference curves generated by an uncoated flow cell and several injections of running buffer. Experimental data were analyzed using BIAevaluation 1.0 software (BIAcore).

X-ray Structure Analysis. Cif-inhibitor cocrystals were obtained by vapor diffusion against 400 μ L of reservoir solution in a 4 μ L hanging drop at 291 K.^{5a,30} A solution of 5 mg/mL Cif protein containing 200 μ M inhibitor was mixed in a 1:1 ratio with reservoir solution consisting of 12-16% (w/v) polyethylene glycol 8000, 125 mM CaCl₂, 100 mM sodium acetate (pH 5), 200 μ M inhibitor, and 0.2% (v/v) DMSO. Prior to data collection, crystals were washed in cryoprotectant solution consisting of 12-16% (w/v) polyethylene glycol 8000, 125 mM CaCl₂, 100 mM sodium acetate (pH 5), 200 µM inhibitor, 0.2% (v/v) DMSO, and 20% (w/v) glycerol and flash cooled by plunging into a liquid nitrogen bath. Oscillation data were collected at 100 K at the X6A beamline of the National Synchrotron Light Source at Brookhaven National Laboratory (PDB code 5HKB) and the 5.0.1 beamline of the Advance Light Source at Lawrence Berkeley National Laboratory (PDB codes 5HKA, 5HK9). Diffraction images were processed and scaled with the XDS package (version January 10, 2014).³¹ Molecular replacement using apo-Cif-WT as the search model (PDB code 3KD2) revealed two dimers in the asymmetric unit. Iterative rounds of automated refinement were carried out with Phenix (version 1.7.3-928).³² WinCoot (version 0.7)³³ was used for manual adjustment of the model, and PyMOL (version 1.3)³⁴ was used to render structure images of the final models of chain B, in which the active-site structures are best defined. Structure figures were assembled in Adobe Illustrator CS6 (version 16.0.4).

Thyroid Hormone Activity Assay. Thyroid hormone activity was measured by the assay described previously with slight modifications.¹⁴ GH3.TRE-Luc cells were seeded at 80% confluency in 75 cm² culture flasks (Corning, Schiphol-Rijk, The Netherlands) in regular growth medium. Cells were collected and seeded into 24-well plates for an additional period of 24 h and incubated for 24 h in the presence or absence of T₃, with the indicated test chemical in DMSO. The DMSO concentration in 500 µL of exposure medium was always the same for all exposures within an experiment and always kept at ≤0.5% (v/v) to avoid cytotoxicity. Cell viability in each well was determined by measuring total protein concentration using the bicinchoninic acid (BCA) assay following the manufacturer's protocol. Luciferase activity was measured on lysed cells on an Infinite M1000 plate reader (Tecan Group AG, Zürich, Switzerland).

ASSOCIATED CONTENT

S Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmed-chem.6b00173.

LC–MS/MS conditions, additional SAR data, SPR data, thyroid hormone activity assay data, and detailed experimental methods (PDF)

Molecular formula strings (CSV)

Accession Codes

Cif:1a complex: 5HKB. Cif:8c complex. 5HKA. Cif:8h complex: 5HK9.

AUTHOR INFORMATION

Corresponding Author

*Phone: 530-752-6571 (office). Fax: 530-752-1537. E-mail: chmorisseau@ucdavis.edu.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We express our sincere thanks and appreciation to Dr. Brenda J. Mengeling and Dr. J. David Furlow for help on the thyroid hormone activity assay; Dr. Vikrant Singh, Brandon Pressly, and Dr. Heike Wulff for kindly providing us thyroid hormone analogs; Dr. Amelia A. Rand, Dr. Jun Yang, and Dr. Debin Wan for their help with LC-MS analysis; Dr. Peter Hwang for assistance on SPR experiments; and Dr. Christopher Bahl for contributions to the cocrystallization and screening experiments. This work was partially funded by the National Institute of Environmental Health Sciences (Grants R01ES002710 and P42 ES04699), the National Institute of Allergy and Infectious Diseases (Grant R01AI091699), the National Institute of General Medical Sciences (Grants P30-GM106394 and T32-GM008704), and the Munck-Pfefferkorn Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. B.D.H. is a George and Judy Marcus Senior Fellow of the American Asthma Foundation. S.K. is financially supported by Japan Student Services Organization.

ABBREVIATIONS USED

CFTR, cystic fibrosis transmembrane conductance regulator; Cif, cystic fibrosis transmembrane conductance regulator inhibitory factor; EH, epoxide hydrolase; T₃, triiodothyronine; sEH, soluble epoxide hydrolase; mEH, microsomal epoxide hydrolase; CMNGC, cyano(6-methoxynaphthalen-2-yl)methyl glycidyl carbonate; *t*-DPPO, [³H]-*trans*-diphenylpropene oxide; TR, thyroid hormone receptor; SPR, surface plasmon resonance

REFERENCES

(1) (a) Dudley, M. N.; Loutit, J.; Griffith, D. C. Aerosol antibiotics: Considerations in pharmacological and clinical evaluation. *Curr. Opin. Biotechnol.* **2008**, *19* (6), 637–643. (b) Davies, J. C.; Bilton, D. Bugs, biofilms, and resistance in cystic fibrosis. *Respir. Care* **2009**, *54* (5), 628–640.

(2) Mah, T.-F.; Pitts, B.; Pellock, B.; Walker, G. C.; Stewart, P. S.; O'Toole, G. A. A genetic basis for *Pseudomonas aeruginosa* biofilm antibiotic resistance. *Nature* **2003**, *426* (6964), 306–310.

(3) (a) Cohen, T. S.; Prince, A. Cystic fibrosis: A mucosal immunodeficiency syndrome. Nat. Med. 2012, 18 (4), 509-519. (b) Stanton, B. A.; Coutermarsh, B.; Barnaby, R.; Hogan, D. Pseudomonas aeruginosa reduces VX-809 stimulated F508del-CFTR chloride secretion by airway epithelial cells. PLoS One 2015, 10 (5), e0127742. (c) Jolly, A. L.; Takawira, D.; Oke, O. O.; Whiteside, S. A.; Chang, S. W.; Wen, E. R.; Quach, K.; Evans, D. J.; Fleiszig, S. M. J. Pseudomonas aeruginosa-induced bleb-niche formation in epithelial cells is independent of actinomyosin contraction and enhanced by loss of cystic fibrosis transmembrane-conductance regulator osmoregulatory function. mBio 2015, 6 (2), e02533-14. (d) Trinh, N. T. N.; Bilodeau, C.; Maillé, É.; Ruffin, M.; Quintal, M.-C.; Desrosiers, M.-Y.; Rousseau, S.; Brochiero, E. Deleterious impact of Pseudomonas aeruginosa on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells. Eur. Respir. J. 2015, 45 (6), 1590-1602. (e) Rubino, R.; Bezzerri, V.; Favia, M.; Facchini, M.; Tebon, M.; Singh, A.; Riederer, B.; Seidler, U.; Iannucci, A.; Bragonzi, A.; Cabrini, G.; Reshkin, S.; Tamanini, A. Pseudomonas aeruginosa reduces the expression of CFTR via post-translational modification of NHERF1. Pfluegers Arch. 2014, 466 (12), 2269-2278.

(4) Ballok, A. E.; O'Toole, G. A. Pouring salt on a wound: *Pseudomonas aeruginosa* virulence factors alter Na+ and Cl- flux in the lung. *J. Bacteriol.* **2013**, *195* (18), 4013–4019.

(5) (a) Bahl, C. D.; Morisseau, C.; Bomberger, J. M.; Stanton, B. A.; Hammock, B. D.; O'Toole, G. A.; Madden, D. R. Crystal structure of

Journal of Medicinal Chemistry

the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor. J. Bacteriol. **2010**, 192 (7), 1785–1795. (b) Bahl, C. D.; Hvorecny, K. L.; Bomberger, J. M.; Stanton, B. A.; Hammock, B. D.; Morisseau, C.; Madden, D. R. Inhibiting an epoxide hydrolase virulence factor from *Pseudomonas aeruginosa* protects CFTR. *Angew. Chem., Int. Ed.* **2015**, 54 (34), 9881–9885. (c) Bahl, C. D.; Madden, D. R. *Pseudomonas aeruginosa* Cif defines a distinct class of α/β epoxide hydrolases utilizing a His/Tyr ring-opening pair. *Protein Pept. Lett.* **2012**, 19 (2), 186–193.

(6) Evans, R. W.; Braverman, L. E. Use of 1251-triiodothyroacetic acid to measure nuclear thyroid hormone receptor. *Endocr. Res.* **1986**, *12* (1), 37–47.

(7) (a) Ma, R. C. W.; Chan, M. H. M.; Poon, W. T.; So, W. Y.; Chow, C. C. Thyroid dysfunction due to over-the-counter usage of tiratricol. *Intern. Med. J.* **2008**, 38 (7), 611–612. (b) Cohen-Lehman, J.; Charitou, M. M.; Klein, I. Tiratricol-induced periodic paralysis: a review of nutraceuticals affecting thyroid function. *Endocr. Pract.* **2011**, *17* (4), 610–615. (c) Marks, D. H. Dangers of OTC herbal supplements: Dilated cardiomyopathy after ingestion of TRIAC (triiodothyroacetic acid, Tiratricol). *Internet J. Endocrinol.* **2006**, 3 (2), 3.

(8) Singh, L.; Pressly, B.; Mengeling, B. J.; Fettinger, J. C.; Furlow, J. D.; Lein, P. J.; Wulff, H.; Singh, V. Chasing the elusive benzofuran impurity of the THR antagonist NH-3: Synthesis, isotope labeling, and biological activity. *J. Org. Chem.* **2016**, *81* (5), 1870–1876.

(9) Berkenstam, A.; Kristensen, J.; Mellström, K.; Carlsson, B.; Malm, J.; Rehnmark, S.; Garg, N.; Andersson, C. M.; Rudling, M.; Sjöberg, F.; Angelin, B.; Baxter, J. D. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. *Proc. Natl. Acad. Sci. U. S. A.* **2008**, *105* (2), 663–667.

(10) (a) Joharapurkar, A. A.; Dhote, V. V.; Jain, M. R. Selective thyromimetics using receptor and tissue selectivity approaches: Prospects for dyslipidemia. *J. Med. Chem.* **2012**, *55* (12), 5649–5675. (b) Baxter, J. D.; Webb, P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. *Nat. Rev. Drug Discovery* **2009**, *8* (4), 308–320.

(11) Chidambaram, R.; Kant, J.; Weaver, R. E., Jr.; Yu, J.; Ghosh, A. Process for the preparation of aniline-derived thyroid receptor ligands with improved safety and economy. WO03039456 A2, May 15, 2003.

(12) Wilcken, R.; Zimmermann, M. O.; Lange, A.; Joerger, A. C.; Boeckler, F. M. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. *J. Med. Chem.* **2013**, *56* (4), 1363–1388.

(13) (a) Sinnokrot, M. O.; Sherrill, C. D. Substituent effects in $\pi - \pi$ interactions: Sandwich and T-shaped configurations. *J. Am. Chem. Soc.* **2004**, 126 (24), 7690–7697. (b) Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist's guide to molecular interactions. *J. Med. Chem.* **2010**, 53 (14), 5061–5084.

(14) Freitas, J.; Cano, P.; Craig-Veit, C.; Goodson, M. L.; Furlow, D. J.; Murk, A. J. Detection of thyroid hormone receptor disruptors by a novel stable in vitro reporter gene assay. *Toxicol. In Vitro* **2011**, *25* (1), 257–266.

(15) (a) Decker, M.; Adamska, M.; Cronin, A.; Di Giallonardo, F.; Burgener, J.; Marowsky, A.; Falck, J. R.; Morisseau, C.; Hammock, B. D.; Gruzdev, A.; Zeldin, D. C.; Arand, M. EH3 (ABHD9): The first member of a new epoxide hydrolase family with high activity for fatty acid epoxides. *J. Lipid Res.* **2012**, *53* (10), 2038–2045. (b) Arand, M.; Wagner, H.; Oesch, F. Asp, Asp, and His form the catalytic triad of rat soluble epoxide hydrolase. *J. Biol. Chem.* **1996**, *271* (8), 4223–4229. (c) Gomez, G. A.; Morisseau, C.; Hammock, B. D.; Christianson, D. W. Human soluble epoxide hydrolase: Structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids. *Protein Sci.* **2006**, *15* (1), 58– 64.

(16) (a) Amano, Y.; Yamaguchi, T.; Tanabe, E. Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography. *Bioorg. Med. Chem.* **2014**, 22 (8), 2427–2434. (b) Morisseau, C.; Goodrow, M. H.;

Dowdy, D.; Zheng, J.; Greene, J. F.; Sanborn, J. R.; Hammock, B. D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. *Proc. Natl. Acad. Sci. U. S. A.* **1999**, *96* (16), 8849–8854. (c) Morisseau, C.; Newman, J. W.; Wheelock, C. E.; Hill, T., III; Morin, D.; Buckpitt, A. R.; Hammock, B. D. Development of metabolically stable inhibitors of mammalian microsomal epoxide hydrolase. *Chem. Res. Toxicol.* **2008**, *21* (4), 951–957. (d) Morisseau, C.; Newman, J. W.; Dowdy, D. L.; Goodrow, M. H.; Hammock, B. D. Inhibition of microsomal epoxide hydrolases by ureas, amides, and amines. *Chem. Res. Toxicol.* **2001**, *14* (4), 409–415.

(17) Bahl, C. D.; Hvorecny, K. L.; Morisseau, C.; Gerber, S. A.; Madden, D. R. Visualizing the mechanism of epoxide hydrolysis by the bacterial virulence enzyme Cif. *Biochemistry* **2016**, *55* (5), 788–797.

(18) Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. *Chem. Rev.* **1995**, 95 (7), 2457–2483.

(19) (a) Nieba, L.; Krebber, A.; Plückthun, A. Competition BIAcore for measuring true affinities: Large differences from values determined from binding kinetics. *Anal. Biochem.* **1996**, 234 (2), 155–165. (b) Schuck, P. Use of surface plasmon resonance to probe the equilibrium and dynamic aspects of interactions between biological macromolecules. *Annu. Rev. Biophys. Biomol. Struct.* **1997**, 26 (1), 541– 566. (c) Cushing, P. R.; Fellows, A.; Villone, D.; Boisguérin, P.; Madden, D. R. The relative binding affinities of PDZ partners for CFTR: A biochemical basis for efficient endocytic recycling. *Biochemistry* **2008**, 47 (38), 10084–10098.

(20) Lee, K. S. S.; Liu, J.-Y.; Wagner, K. M.; Pakhomova, S.; Dong, H.; Morisseau, C.; Fu, S. H.; Yang, J.; Wang, P.; Ulu, A.; Mate, C. A.; Nguyen, L. V.; Hwang, S. H.; Edin, M. L.; Mara, A. A.; Wulff, H.; Newcomer, M. E.; Zeldin, D. C.; Hammock, B. D. Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. *J. Med. Chem.* **2014**, *57* (16), 7016–7030.

(21) Kim, I. H.; Nishi, K.; Kasagami, T.; Morisseau, C.; Liu, J.-Y.; Tsai, H. J.; Hammock, B. D. Biologically active ester derivatives as potent inhibitors of the soluble epoxide hydrolase. *Bioorg. Med. Chem. Lett.* **2012**, *22* (18), 5889–5892.

(22) Baojian, W.; Sumit, B.; Shengnan, M.; Xiaoqiang, W.; Ming, H. Regioselective sulfation and glucuronidation of phenolics: Insights into the structural basis. *Curr. Drug Metab.* **2011**, *12* (9), 900–916.

(23) Smith, D. A.; Di, L.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery. *Nat. Rev. Drug Discovery* **2010**, *9* (12), 929–939.

(24) Bomberger, J. M.; Ye, S.; MacEachran, D. P.; Koeppen, K.; Barnaby, R. L.; O'Toole, G. A.; Stanton, B. A. A *Pseudomonas aeruginosa* toxin that hijacks the host ubiquitin proteolytic system. *PLoS Pathog.* **2011**, 7 (3), e1001325.

(25) Prosser, G. A.; Larrouy-Maumus, G.; de Carvalho, L. P. S. Metabolomic strategies for the identification of new enzyme functions and metabolic pathways. *EMBO Rep.* **2014**, *15* (6), 657–669.

(26) MacEachran, D. P.; Ye, S.; Bomberger, J. M.; Hogan, D. A.; Swiatecka-Urban, A.; Stanton, B. A.; O'Toole, G. A. The *Pseudomonas aeruginosa* secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator. *Infect. Immun.* **2007**, 75 (8), 3902–3912.

(27) Morisseau, C.; Merzlikin, O.; Lin, A.; He, G.; Feng, W.; Padilla, I.; Denison, M. S.; Pessah, I. N.; Hammock, B. D. Toxicology in the fast lane: Application of high-throughput bioassays to detect modulation of key enzymes and receptors. *Environ. Health Perspect.* **2009**, *117* (12), 1867–1872.

(28) (a) Morisseau, C.; Bernay, M.; Escaich, A.; Sanborn, J. R.; Lango, J.; Hammock, B. D. Development of fluorescent substrates for microsomal epoxide hydrolase and application to inhibition studies. *Anal. Biochem.* **2011**, 414 (1), 154–162. (b) Jones, P. D.; Wolf, N. M.; Morisseau, C.; Whetstone, P.; Hock, B.; Hammock, B. D. Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. *Anal. Biochem.* **2005**, 343 (1), 66–75.

(29) Morisseau, C.; Goodrow, M. H.; Newman, J. W.; Wheelock, C. E.; Dowdy, D. L.; Hammock, B. D. Structural refinement of inhibitors

Journal of Medicinal Chemistry

Article

of urea-based soluble epoxide hydrolases. *Biochem. Pharmacol.* 2002, 63 (9), 1599–1608.

(30) Bahl, C. D.; MacEachran, D. P.; O'Toole, G. A.; Madden, D. R. Purification, crystallization and preliminary X-ray diffraction analysis of Cif, a virulence factor secreted by *Pseudomonas aeruginosa. Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun.* **2010**, *66* (Part 1), 26–28.

(31) Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. *J. Appl. Crystallogr.* **1993**, *26*, 795–800.

(32) Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* 2010, 66 (2), 213–221.

(33) Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular graphics. *Acta Crystallogr, Sect. D: Biol. Crystallogr.* 2004, 60 (Part 12, Part 1), 2126–2132.

(34) DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific LLC: Palo Alto, CA, U.S., 2008; http://www.pymol.org.

(35) Ulu, A.; Appt, S.; Morisseau, C.; Hwang, S. H.; Jones, P. D.; Rose, T. E.; Dong, H.; Lango, J.; Yang, J.; Tsai, H. J.; Miyabe, C.; Fortenbach, C.; Adams, M. R.; Hammock, B. D. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. *Br. J. Pharmacol.* **2012**, *165* (5), 1401–1412.